Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Allopurinol
Drug ID BADD_D00076
Description Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Indications and Usage For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.
Marketing Status Prescription; Discontinued
ATC Code M04AA01
DrugBank ID DB00437
KEGG ID D00224
MeSH ID D000493
PubChem ID 135401907
TTD Drug ID D04KYY
NDC Product Code 50268-063; 49711-0113; 16714-041; 0603-2116; 14445-001; 69967-008; 55700-879; 50090-4662; 23155-694; 53489-156; 0591-5544; 0904-7041; 0378-0181; 55700-935; 66267-665; 61919-748; 50090-5194; 67457-187; 51079-206; 63739-796; 43063-976; 68083-380; 23155-693; 70518-1678; 71335-0112; 17351-0041; 55700-540; 67296-1265; 71610-253; 63629-2113; 51079-205; 50268-064; 29300-350; 68071-2660; 70934-072; 55700-947; 55154-5534; 50090-0044; 70934-389; 61919-471; 55111-730; 68071-1805; 71610-197; 70518-3289; 70710-1210; 63629-1781; 58118-1156; 67296-1314; 49452-0008; 70518-1806; 65015-606; 16729-135; 0904-6571; 63552-151; 70771-1127; 55154-2338; 62584-988; 70199-016; 70710-1209; 43353-088; 55154-7892; 16729-134; 0615-8385; 0591-5543; 68108-0212; 71205-208; 63629-8020; 43063-975; 71335-0467; 70771-1126; 68071-2616; 63187-240; 53002-4821; 36974-0018; 50090-2544; 69967-009; 70934-504; 63629-7908; 0615-8321; 51927-0070; 71610-064; 63629-2111; 50090-5168; 71610-194; 60760-134; 53002-4820; 65219-380; 70934-295; 65977-0124; 43063-793; 70199-015; 67457-978; 71610-231; 67544-736; 50090-3760; 43063-079; 71205-377; 62584-713; 71205-049; 50090-4663; 63629-1675; 63552-150; 0378-0137; 16714-042; 16714-577; 55154-7981; 16714-576; 43063-935; 29300-349; 70934-209; 70518-0451; 55289-010; 43353-186; 0603-2115; 55154-5454; 43063-774; 71335-1656; 55111-729; 60760-139; 0904-6572; 63629-2112; 70934-681; 43063-934; 50090-3758; 63739-410; 57451-1166; 60429-180; 66064-2100; 51927-1915; 66267-224; 68788-7542; 53489-157; 63187-463; 70518-1573; 68788-7383
Synonyms Allopurinol | Uribenz | Allopurin | Allorin | Allpargin | Allural | Pan Quimica | Apulonga | Apurin | Atisuril | Bleminol | Caplenal | Capurate | Cellidrin | Embarin | Suspendol | Foligan | Hamarin | Lopurin | Lysuron | Jenapurinol | Milurit | Milurite | Novopurol | Uripurinol | Urosin | Urtias | Xanthomax | Uridocid | Xanturic | Zygout | Zyloprim | Zyloric | Pureduct | Purinol | Progout | Remid | Rimapurinol | Roucol | Tipuric | Allohexal | Allohexan | Alloprin
Chemical Information
Molecular Formula C5H4N4O
CAS Registry Number 315-30-0
SMILES C1=NNC2=C1C(=O)NC=N2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Aplasia pure red cellGlycophorin-AP02724Not Available10398315; 16076905; 11816258
Reperfusion injuryIntercellular adhesion molecule 1P05362T2620314614706; 9583490; 9744646
Reperfusion injuryMyeloperoxidaseP05164T2347114614706; 9583490; 9744646
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary artery stenosis24.04.09.011; 22.06.03.0060.000132%Not Available
Symblepharon06.06.02.0120.000395%Not Available
Trichiasis23.02.06.011; 06.06.04.0230.000329%Not Available
Uraemic encephalopathy20.01.01.011; 17.13.01.012; 14.10.01.0090.000132%Not Available
Rheumatoid vasculitis24.05.02.023; 15.01.03.006; 10.04.06.0080.000329%Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis24.05.02.016; 10.02.02.0230.000461%Not Available
Lip erosion07.05.01.0160.000264%Not Available
Necrotising ulcerative gingivostomatitis11.02.29.001; 07.05.07.0180.000103%Not Available
General physical condition abnormal13.15.01.0400.000132%Not Available
Human herpes virus 6 serology positive13.08.03.0250.000132%Not Available
Age-related macular degeneration06.09.03.0180.000132%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000132%Not Available
Human herpesvirus 8 infection11.05.02.033; 10.03.03.0080.000132%Not Available
Left atrial dilatation02.04.02.0250.000132%Not Available
Skin plaque23.03.03.0440.000198%Not Available
Ocular pemphigoid23.03.01.030; 10.04.04.015; 06.04.05.0300.000198%Not Available
HLA marker study positive13.22.01.0110.000527%Not Available
Interstitial granulomatous dermatitis10.04.02.016; 23.03.15.0070.000132%Not Available
Overlap syndrome10.04.04.016; 23.03.02.018; 15.06.01.0160.000395%Not Available
Roseolovirus test positive13.08.03.0320.000132%Not Available
Prerenal failure24.06.02.025; 20.01.03.0220.000198%Not Available
Fulminant type 1 diabetes mellitus14.06.01.013; 05.06.01.0130.000329%Not Available
HLA-B*5801 assay positive13.22.01.0120.000329%Not Available
Autoimmune hypothyroidism05.02.03.005; 10.04.08.0090.000264%Not Available
The 22th Page    First    Pre   22    Total 22 Pages